Gundara Justin S, Zhao Jing Ting, Gill Anthony J, Clifton-Bligh Roderick, Robinson Bruce G, Delbridge Leigh, Sidhu Stan B
Cancer Genetics Laboratory, Kolling Institute of Medical Research, Royal North Shore Hospital, St. Leonards, Sydney, New South Wales, Australia; Endocrine Surgical Unit, Royal North Shore Hospital, St. Leonards, Sydney, New South Wales, Australia; University of Sydney, Sydney, New South Wales, Australia; Northern Translational Cancer Research Unit, Kolling Institute of Medical Research, Royal North Shore Hospital, St. Leonards, Sydney, New South Wales, Australia.
ANZ J Surg. 2014 Apr;84(4):235-9. doi: 10.1111/j.1445-2197.2012.06291.x. Epub 2012 Oct 16.
Lymph node metastases represent a diagnostic and management challenge in patients with disseminated medullary thyroid carcinoma (MTC). Our understanding of microRNA (miRNA) profiles of metastatic disease also remains limited and may unveil novel therapeutic strategies for these patients.
MTC patients with a history of total thyroidectomy and lymph node dissection were identified from within the prospective Sydney University Endocrine Surgical Unit database. Patients with available formalin-fixed paraffin-embedded tumour tissue were included and clinicopathological data were collated. Total RNA was extracted and quantitave polymerase chain reaction (qPCR) analysis performed on the primary tumour and a corresponding lymph node metastasis for expression of miRNAs of proven significance in MTC (miR-9*, miR-183 and miR-375).
Tissue was available for analysis in seven patients. The median age at diagnosis was 55 years (range: 22-67). Median tumour size was 18 mm (range: 6-55) and over a median follow-up period of 34 months (range: 1-210), five further operations were undertaken for residual disease. One patient died of metastatic disease. Pairwise correlations of qPCR expression levels between primary tumours and corresponding lymph node metastases revealed significant correlations for miR-9* (P < 0.001), miR-183 (P = 0.001) and miR-375 (P = 0.004).
miRNA expression patterns in nodal metastases significantly reflect those of the primary tumour in MTC. This further validates previously reported miRNA profile analyses and reiterates the potential significance of miR-9*, -183 and -375 in the pathophysiology of MTC. The possibility of lymph node biopsy miRNA analysis driven clinical decision making may now also be a possibility where conventional techniques are unhelpful.
淋巴结转移对散发性甲状腺髓样癌(MTC)患者的诊断和治疗构成挑战。我们对转移性疾病的微小RNA(miRNA)谱的了解仍然有限,而这可能会为这些患者揭示新的治疗策略。
从悉尼大学前瞻性内分泌外科数据库中识别出有全甲状腺切除术和淋巴结清扫病史的MTC患者。纳入有可用福尔马林固定石蜡包埋肿瘤组织的患者,并整理临床病理数据。提取总RNA,并对原发性肿瘤和相应的淋巴结转移灶进行定量聚合酶链反应(qPCR)分析,以检测在MTC中已证实具有重要意义的miRNA(miR-9*、miR-183和miR-375)的表达。
7例患者有可供分析的组织。诊断时的中位年龄为55岁(范围:22 - 67岁)。中位肿瘤大小为18毫米(范围:6 - 55毫米),在中位随访期34个月(范围:1 - 210个月)内,因残留疾病又进行了5次手术。1例患者死于转移性疾病。原发性肿瘤与相应淋巴结转移灶之间qPCR表达水平的成对相关性显示,miR-9*(P < 0.001)、miR-183(P = 0.001)和miR-375(P = 0.004)具有显著相关性。
MTC中淋巴结转移灶的miRNA表达模式显著反映了原发性肿瘤的表达模式。这进一步验证了先前报道的miRNA谱分析,并再次强调了miR-9*、-183和-375在MTC病理生理学中的潜在重要性。在传统技术无用的情况下,通过淋巴结活检miRNA分析推动临床决策现在也成为了一种可能。